Last reviewed · How we verify

Tree SLIT-tablet

ALK-Abelló A/S · Phase 3 active Small molecule

Tree SLIT-tablet is a sublingual immunotherapy that desensitizes the immune system to tree pollen allergens by gradually exposing patients to increasing doses of allergen extract.

Tree SLIT-tablet is a sublingual immunotherapy that desensitizes the immune system to tree pollen allergens by gradually exposing patients to increasing doses of allergen extract. Used for Allergic rhinitis and/or allergic asthma caused by tree pollen allergens.

At a glance

Generic nameTree SLIT-tablet
SponsorALK-Abelló A/S
Drug classAllergen immunotherapy (sublingual tablet)
TargetTree pollen allergen epitopes
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhasePhase 3

Mechanism of action

SLIT (sublingual immunotherapy) works by placing allergen tablets under the tongue, where they interact with immune cells in the oral mucosa. This repeated, controlled exposure induces immune tolerance through regulatory T cell expansion and shift from Th2 to Th1/Treg responses, reducing allergic symptoms and the need for symptomatic medications. The mechanism is similar to subcutaneous immunotherapy but delivered via the sublingual route for improved tolerability and convenience.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results